Our Clients

  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • FAQs

    Global Prefilled Syringes Market size was valued at USD 7.52 Billion in 2024 and is poised to grow from USD 8.32 Billion in 2025 to USD 18.62 Billion by 2033, growing at a CAGR of 10.6% during the forecast period (2026–2033).

    The prefilled syringes market is particularly competitive and dynamic, with each installed pharmaceutical giants and specialized medical tool agencies actively engaged in driving innovation, enhancing patient safety, and increasing their international presence. These competitive environments are fashioned by way of elements such as technological advancements, strategic partnerships, acquisitions, and the consistent need for addressing stringent regulatory requirements. 'Becton, Dickinson and Company (BD) (USA)', 'Gerresheimer AG (Germany) ', 'Schott AG (Germany) ', 'Baxter International Inc. (USA) ', 'Cardinal Health, Inc. (USA) ', 'Terumo Corporation (Japan) ', 'West Pharmaceutical Services, Inc. (USA) ', 'Nipro Corporation (Japan) ', 'Ompi (Italy) ', 'SGD Pharma (France) ', 'Stevanato Group (Italy) ', 'Medtronic plc (Ireland) ', 'Fresenius Kabi AG (Germany) ', 'Ypsomed Holding AG (Switzerland) ', 'ARaymondlife SAS (France) ', 'Credence MedSystems, Inc. (USA) ', 'Nemera (France) ', 'Taisei Kako Co., Ltd. (Japan) ', 'Weigao Group (China) ', 'Braun Melsungen AG (Germany)'

    Increasing incidence of chronic diseases such as diabetes mellitus, rheumatoid arthritis and rheumatoid arthritis has created demand for vaccines which are commonly administered by injection has increased dramatically. The demand for prefilled syringes has been amplified. The power of a syringe a controlled packaging can reduce the risk of contamination and minimize dose errors makes it the best option for vaccines and therapeutics strong application in nature, leading to market growth. 

    Transition to Polymer-Based Prefilled Syringes: Traditionally glass has been the preferred material for prefilled syringes, due to its inertness and compatibility with a wide range of chemicals but polymer-based prefilled syringes are gaining popularity. Polymeric materials such as cyclic olefin polymers (COP) and cyclic olefin copolymers (COCs) increase strength and reduce the risk of contamination from glass breakage. These materials are particularly useful for biologics and complex pharmaceuticals requiring accurate and robust quantification. The trend toward polymer-based syringes is expected to increase as pharmaceutical companies seek safer and more durable products than glass.

    North America region in the prefilled syringes market share is 32.3% in 2023. Prevention of needlestick injuries by healthcare professionals is a priority in developed countries including the US. and Canada including in pre-filled syringes with needle guards decrease the likelihood of this injury. Centers for Disease Control for Vaccine Administration owing to their ability to preserve vaccine potency over a long period of time and shelf life driving the market growth. North America accounted for the largest share of the pre-filled syringes market in 2023. Also, injection devices, improved medication regimens, technological advances, routine prescriptions of self-administered devices and Prevention (CDC) recommendations are expected to deliver the market has developed. 

    Feedback From Our Clients

    Global Prefilled Syringes Market

    Report ID: SQSG35B2013

    $5,300
    BUY NOW